Sign inCreate account

Report workspace tools

NCT00927459TERMINATEDanonymous

A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-040201 in Male and Female Subjects With Hypercholesterolemia

Sponsor

Source record

Arbutus Biopharma Corporation

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

PRO-040201, Placebo

Indication / condition

AI-normalized

Hypercholesterolemia

Intervention

Source record

PRO-040201, Placebo

Source & freshness

Source record

NCT ID

NCT00927459

Original source

ClinicalTrials.gov

Source last updated

Jan 22, 2010

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00927459

Title

A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-040201 in Male and Female Subjects With Hypercholesterolemia

Sponsor

Arbutus Biopharma Corporation

Status

TERMINATED

Phase

PHASE1

Condition raw

Hypercholesterolemia

Condition normalized

Hypercholesterolemia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

PRO-040201, Placebo

Target normalized

PRO-040201, Placebo

Interventions

PRO-040201, Placebo

Public preview

Source record

This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study in male and female subjects with high cholesterol. A maximum of 32 subjects is planned for enrollment in this study.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-040201 in Male and Female Subjects With Hypercholesterolemia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00927459

Status

TERMINATED

Phase

PHASE1

Sponsor

Arbutus Biopharma Corporation

Executive brief

Investment-Ready Snapshot

This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study in male and female subjects with high cholesterol. A maximum of 32 subjects is planned for enrollment in this study.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 22, 2010
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00927459

Indication

Hypercholesterolemia

Modality

small molecule

Target

PRO-040201, Placebo

Intervention

PRO-040201, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.